RxDoctor Payments Data

Robert Grodman, DO

Cardiovascular Disease · Livonia, MINPI 1164495313

Payments from drug & device makers

$35,442in general payments, 2019–2025

Across 543 payments — averaging $65.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor (international) Ltd.$12K
  • Novartis$8K
  • Boston Scientific$4K
  • Abbott$2K
  • Kowa Research Institute, Inc.$2K
  • Johnson & Johnson$2K
  • plus $7K from 40 others

What the payments were for

  • Travel & lodging$2,21215%
  • Food & beverage$12,27084%
  • Education$630%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,442 in reported general payments places this provider in the 80th percentile of 760 cardiovascular disease providers in Michigan.

See all cardiovascular disease providers in Michigan

Medicare billing

Part B allowed, 2024
$296,192
Medicare patients
889
Services billed
3,812

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban246$337,464
XareltoRivaroxaban107$127,726
EntrestoSacubitril/Valsartan96$119,206
Repatha SureclickEvolocumab120$74,202
MultaqDronedarone Hcl21$31,780
FarxigaDapagliflozin Propanediol22$22,321
BrilintaTicagrelor18$20,503
Praluent PenAlirocumab30$15,389
Metoprolol Succinate468$8,537
Ranolazine ErRanolazine33$5,233
ClopidogrelClopidogrel Bisulfate250$4,622
Atorvastatin Calcium384$4,299
Flecainide Acetate32$3,543
Nebivolol Hcl45$3,539
Rosuvastatin Calcium171$3,193

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$415$337,464246 claims
Johnson & JohnsonXarelto$1,631$127,726107 claims
NovartisEntresto$7,784$119,20696 claims
AstraZenecaFarxiga, Brilinta$590$42,82440 claims
Sanofi-aventis U.S. LLCMultaq$184$31,78021 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 760 cardiovascular disease providers in Michigan.

Other cardiovascular disease in Livonia

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →